US stock · Healthcare sector · Drug Manufacturers—General
Company Logo

AbbVie Inc.

ABBVNYSE

145.02

USD
-0.18
(-0.12%)
After Hours Market
19.36P/E
12Forward P/E
0.88P/E to S&P500
256.465BMarket CAP
3.88%Div Yield
Upcoming Earnings
9 Feb
Shares Short
1/13/23
11.96M
Short % of Float
0.68%
Short % of Shares Outs.
0.68%
% Held by Insiders
0.11%
% Held by Institutions
70.90%
Beta
0.62
PEG Ratio
-3.61
52w. high/low
175.91/134.09
Avg. Daily Volume
5.48M
Return %
Stock
S&P 500
1 year
2.97
(7.99)
3 years
66.72
23.80
5 years
35.37
56.27
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
54.78
33.33
70.76
45.50
71.60
45.45
68.12
50.71
99.10
59.27
125.86
77.50
92.30
62.66
109.15
62.55
136.83
101.81
175.91
128.26
168.11
143.44
Currency: USD
- -
- -
- -
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
9.00
9.90
11.04
11.66
11.84
12.54
14.20
16.10
17.72
22.15
22.49
25.95
31.78
32.66
Earnings per share
- -
- -
- -
2.93
2.64
2.17
3.34
2.60
1.11
3.20
3.74
3.33
3.85
5.33
2.62
6.53
7.55
FCF per share
- -
- -
- -
3.20
2.87
3.73
3.81
3.64
1.85
4.35
4.12
5.92
8.65
8.64
9.51
12.44
12.38
Dividends per share
- -
- -
- -
- -
- -
- -
- -
1.61
1.67
2.05
2.33
2.58
3.77
4.30
4.37
5.24
5.57
CAPEX per share
- -
- -
- -
0.20
0.28
0.23
0.21
0.31
0.38
0.33
0.30
0.33
0.43
0.37
0.45
0.45
0.38
Book Value per sh.
- -
- -
- -
- -
9.94
7.74
2.13
2.83
1.09
2.45
2.91
3.20
(5.71)
(5.53)
7.41
8.71
8.80
Comm.Shares outs.
- -
- -
- -
1,580
1,580
1,580
1,577
1,587
1,591
1,610
1,593
1,592
1,479
1,479
1,765
1,768
1,770
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
16.7
49.7
19.2
16.1
22.4
25.3
14.5
34.4
17.3
19.4
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
1.0
2.7
1.0
0.7
1.0
1.0
0.6
0.9
0.6
0.9
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
3.7%
3.0%
3.3%
3.9%
3.4%
3.9%
5.6%
4.9%
4.6%
3.7%
Revenue (m)
- -
- -
- -
14,214
15,638
17,444
18,380
18,790
19,960
22,859
25,638
28,216
32,753
33,266
45,804
56,197
57,819
Operating margin
- -
- -
- -
34.7%
30.2%
20.8%
31.6%
30.1%
17.1%
33.0%
36.6%
34.0%
19.5%
39.0%
24.8%
31.9%
30.6%
Depreciation (m)
- -
- -
- -
697
1,184
1,272
1,150
897
786
836
1,189
1,501
1,765
2,017
6,471
8,521
8,289
Net profit (m)
- -
- -
- -
4,637
4,178
3,433
5,275
4,128
1,774
5,144
5,953
5,309
5,687
7,882
4,616
11,542
13,407
Income tax rate
- -
- -
- -
22.1%
13.6%
6.4%
7.9%
22.6%
25.1%
22.6%
24.5%
31.3%
(9.4)%
6.5%
(36.0)%
11.1%
11.5%
Net profit margin
- -
- -
- -
32.6%
26.7%
19.7%
28.7%
22.0%
8.9%
22.5%
23.2%
18.8%
17.4%
23.7%
10.1%
20.5%
23.3%
Working capital (m)
- -
- -
- -
- -
4,457
1,457
8,578
10,969
4,688
5,420
6,406
4,582
(294)
33,934
(4,488)
(7,266)
(2,348)
Long-term debt (m)
- -
- -
- -
- -
- -
- -
14,630
14,292
10,565
29,240
36,440
30,953
35,002
62,975
77,554
64,189
60,399
Equity (m)
- -
- -
- -
- -
15,703
12,224
3,363
4,492
1,742
3,945
4,636
5,097
(8,446)
(8,172)
13,076
15,408
15,994
ROIC
- -
- -
- -
- -
24.0%
24.9%
26.5%
19.5%
13.0%
13.5%
12.0%
11.3%
17.0%
13.0%
6.5%
12.3%
13.9%
Return on capital
- -
- -
- -
- -
22.9%
18.7%
21.6%
19.3%
10.2%
13.9%
13.5%
12.5%
11.0%
11.5%
3.9%
10.5%
12.0%
Return on equity
- -
- -
- -
- -
26.6%
28.1%
156.9%
91.9%
101.8%
130.4%
128.4%
104.2%
(67.3)%
(96.5)%
35.3%
74.9%
83.8%
Plowback ratio
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
38.1%
(50.0)%
36.0%
37.6%
22.6%
1.9%
19.2%
(66.9)%
19.8%
26.5%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
49.8%
112.8%
155.1%
148.6%
58.5%
137.6%
54.8%
51.8%
46.4%
52.3%
Capital Structure
4 Nov · 2022 | Q3
All numbers in millions
Total liabilities
$ 125,298
Total assets
$ 141,325
Long-term debt
$ 60,399
Cash and equiv.
$ 11,832
Goodwill
$ 31,726
Retained earnings
$ 4,953
Common stock
1,771
Enterprise Value
$ 305,032
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
39,924
8,479
9,830
Receivables
5,428
8,822
9,977
Inventory
1,813
3,310
3,128
Other
2,354
(27,913)
(25,185)
Current assets
49,519
24,173
27,928
Acc. Payable
1,452
2,276
2,882
Debt due
3,753
8,502
12,495
Other
10,380
17,883
19,817
Current liabilities
15,585
28,661
35,194
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
22.69%
19.51%
13.69%
Cash flow
30.97%
24.48%
24.52%
Earnings
150.04%
38.58%
30.05%
Dividends
20.02%
22.80%
- -
Book value
17.83%
(127.78)%
(42.76)%
Insider Trading
Type
Shares
Date
Rapp Edward J
Award
239
12/31/22
Alpern Robert J
Award
46
12/31/22
Richmond Timothy J.
Exempt
42,370
12/12/22
Richmond Timothy J.
Sale
3,075
12/12/22
Richmond Timothy J.
Sale
39,295
12/12/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
8,619
10,425
12,902
13,858
45,804
2021
13,010
13,959
14,342
14,886
56,197
2022
13,538
14,583
14,812
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.71
(0.42)
1.31
0.02
2.62
2021
2.01
0.43
1.80
2.29
6.53
2022
2.54
0.52
2.23
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
1.00
0.99
1.19
1.19
4.37
2021
1.31
1.31
1.31
1.31
5.24
2022
1.43
1.42
1.41
- -
- -
Company Description
Sector:
Healthcare
Industry:
Drug Manufacturers—General
CEO:
Mr. Richard Gonzalez
Full-time employees:
50,000
City:
North Chicago
Address:
1 N Waukegan Rd
IPO:
Jan 2, 2013
Website:
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.